Recent data presented at ESMO 2020 have shown that checkpoint inhibitors may have a beneficial role in the treatment of patients with oesophageal and gastric cancer.
In this podcast, Dr Claudia Cardone interviews Dr Elizabeth Smyth for highlights on upper gastrointestinal tumours, following the ESMO 2020 Virtual Congress.
Dr Smyth comments on the practice-changing data from KEYNOTE 590 and CHECKMATE 649 trials, both investigating the addition of immunotherapy to first line chemotherapy, and from CHECKMATE 577, assessing the efficacy of immunotherapy as adjuvant treatment in patients with oesophageal cancer. The three studies are discussed in the context of current treatment options, future treatment strategies, and implication for patient selection.
Acknowledgments
Funding
None.
Disclosure
The authors declare there are no competing interests in regards to this podcast. ES reports personal financial interests (lecture honoraria, advisory boards, travel support) from Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks outside the submitted work.
Appendix
Further reading
- 1.Kato K., Jun J.-M., Shah M.A. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(suppl 4):S1192–S1193. [Google Scholar]
- 2.Kelly R.J., Ajani J.A., Kuzdzal J. LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Ann Oncol. 2020;31(suppl 4):S1193–S1194. [Google Scholar]
- 3.Moehler M., Shitara K., Garrido M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. 2020;31(suppl 4):S1191. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.